Jnana Therapeutics
Enlightened innovation. Expansive therapeutic impact.
Boston, United States · Founded 2017 · $207.0M raised
- Headquarters
- Boston, Massachusetts
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- jnanatx.com
- Total Funding
- $207.0M
- Last Round
- $107.0M Series CNov 2022
- Rounds
- 3
About
Jnana Therapeutics is a clinical-stage biotechnology company founded in 2017 and headquartered in Boston, Massachusetts, that leverages its proprietary RAPID chemoproteomics platform to discover small molecule medicines for rare genetic metabolic and immune-mediated diseases. The RAPID platform enables systematic identification of unique binding sites on highly validated but historically hard-to-drug protein targets, dramatically accelerating the path from target to clinical candidate. Jnana's lead program, JNT-517, is an oral allosteric inhibitor targeting phenylketonuria (PKU), a serious inherited metabolic disorder; in 2024 the company was acquired by Otsuka Pharmaceutical for approximately $800 million, becoming a subsidiary of Otsuka America.
Summary
Jnana Therapeutics is a Biotech company based in Boston, United States, founded in 2017. It has raised $207.0M in total across 3 rounds, most recently a $107.0M Series C round in Nov 2022. Investors include RA Capital Management, Polaris Partners and Bain Capital Life Sciences.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2022
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.